Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 2 of 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Efficacy of Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration
    (Mongolian National University of Medical Sciences, 2022-12-29) ; ; ;
    Baasankhuu Jamianjav
    ;
    Objective: To study the effect of cataract surgery with intravitreal bevacizumab therapy on visual and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) in Mongolian patients. Methods: A retrospective analysis of 72 eyes of 36 patients with neovascular AMD evaluated intravitreal bevacizumab (1or2.5 mg) injections. Retreatment was performed following an optical coherence tomography (OCT)-based regimen. Ophthalmic examination included best-corrected visual acuity (BCVA), dilated fundus examination, and OCT image analysis. Results: A total of 11 patients received cataract surgery. We could not observe statistical significance between the two groups. The BCVA of the right eye of patients having cataract surgery improved by 0.21 ± 0.29, while the corresponding value for patients without surgery was 0.32 ± 0.32. The mean central retinal thickness (CRT) of patients with refraction was decreased from 264.4 ± 82.32 μm at baseline to 244.55 ± 52.59 μm for the right eye, while it was 275.4 ± 96.4 μm at baseline to 276.36 ± 68.22 μm for the left eye. Conclusion: Cataract surgery with intravitreal bevacizumab therapy in eyes with neovascular AMD in aged patients was performed.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema
    (Mongolian National University of Medical Sciences, 2016-06-25)
    Anaraa Toishubai
    ;
    ;
    Baasankhuu Jamyanjav
    ;
    Sun Taek Lim
    ;
    Objectives: To evaluate the efficacy and safety of bevacizumab monotherapy and bevacizumab therapy combined with laser therapy versus laser monotherapy in Mongolian patients with visual impairment due to diabetic macular edema (DME). Methods: One hundred twelve eligible patients, aged ^18 years, with type 1 or 2 diabetes mellitus and best corrected visual acuity (BCVA) in the study eye of 35 to 69 Early Treatment Diabetic Retinopathy Study letters at 4 m (Snellen equivalent: >6/60 or <6/12), and with visual impairment due to center-involved DME were included in the study. Patients were randomized into three treatment groups: (1) intravitreal bevacizumab monotherapy (n = 42), (2) intravitreal bevacizumab combined with laser therapy (n = 35), and (3) laser monotherapy (n = 35). Bevacizumab injections were given for three initial monthly doses and then pro re nata thereafter based on BCVA stability and DME progression. The primary efficacy endpoints were the mean change in BCVA and central retinal subfield thickness from baseline to month 12. Results: Bevacizumab monotherapy and bevacizumab + laser were superior to laser monotherapy in improving the mean change in BCVA letter score from baseline to month 12 (+8.3 and +11.3 vs +1.1 letters; both p ><0.0001). At month 12, a greater proportion of patients gained >10 and >15 letters and had a BCVA letter score >73 (Snellen equivalent: >6/12) with bevacizumab monotherapy (23.8% and 7.1% and 4.8%, respectively) and bevacizumab + laser (57.1% and 28.6% and 14.3%, respectively) versus laser monotherapy (0% and 0% and 0%, respectively). The mean central retinal subfield thickness was significantly reduced from baseline to month 12 with bevacizumab (-124.4 pm) and bevacizumab + laser (-129.0 pm) versus laser (-62.0 pm; both p = 0.002). Conjunctival hemorrhage was the most common ocular event. No endophthalmitis cases occurred. Conclusion: Bevacizumab monotherapy or bevacizumab + laser showed superior BCVA improvements over macular laser treatment alone in Mongolian patients with visual impairment due to DME.